NeuroDerm Ltd. (NASDAQ:NDRM) shares saw an uptick in trading volume on Wednesday . 76,500 shares traded hands during mid-day trading, an increase of 23% from the previous session’s volume of 62,311 shares.The stock last traded at $17.35 and had previously closed at $17.35.

Several brokerages have weighed in on NDRM. Jefferies Group increased their target price on NeuroDerm from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, September 6th. Roth Capital reaffirmed a “buy” rating on shares of NeuroDerm in a research report on Sunday, May 29th. Finally, Zacks Investment Research lowered NeuroDerm from a “hold” rating to a “sell” rating in a research report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $27.00.

The firm’s market capitalization is $379.17 million. The stock has a 50-day moving average of $17.26 and a 200-day moving average of $16.58.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/neuroderm-ltd-ndrm-sees-large-volume-increase.html

NeuroDerm (NASDAQ:NDRM) last issued its quarterly earnings data on Thursday, August 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.32). Equities analysts expect that NeuroDerm Ltd. will post ($1.49) EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Scopia Capital Management LP increased its position in shares of NeuroDerm by 23.1% in the first quarter. Scopia Capital Management LP now owns 3,383,359 shares of the company’s stock worth $47,773,000 after buying an additional 634,321 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its position in shares of NeuroDerm by 209.7% in the second quarter. Menora Mivtachim Holdings LTD. now owns 590,724 shares of the company’s stock worth $9,599,000 after buying an additional 400,000 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of NeuroDerm during the first quarter worth about $2,349,000. Sectoral Asset Management Inc. purchased a new position in shares of NeuroDerm during the second quarter worth about $1,706,000. Finally, BlackRock Fund Advisors increased its position in shares of NeuroDerm by 29.1% in the first quarter. BlackRock Fund Advisors now owns 342,315 shares of the company’s stock worth $4,833,000 after buying an additional 77,078 shares during the last quarter. 42.82% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroDerm

NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages.

5 Day Chart for NASDAQ:NDRM

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.